Editorial NeuroAIDS review

AIDS

Volumn 25, Issue 2, 2011, Pages 123-141

  Shapshak, Paul ^a,b   Kangueane, Pandjassarame ^c,d   Fujimura, Robert K ^e   Commins, Deborah ^f   Chiappelli, Francesco ^g   Singer, Elyse ^h   Levine, Andrew J ^h   Minagar, Alireza ⁱ   Novembre, Francis J ^j   Somboonwit, Charurut ^a,k   Nath, Avindra ^l   Sinnott, John T ^a,k  

^a TAMPA GENERAL HOSPITAL   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Biomedical Informatics   (India)

^d AIMST UNIVERSITY   (Malaysia)

^e Veterans Administration   (United States)

^f UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^g UCLA SCHOOL OF DENTISTRY   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ Louisiana State University School of Medicine Shreveport   (United States)

^j EMORY UNIVERSITY   (United States)

^k Clinical Research Unit   (United States)

^l JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

animal models; evolution; gene expression; genetics; HIV 1; HIV associated neurocognitive disorder; molecular therapy; NeuroAIDS; vaccines; virus load

Indexed keywords

ENFUVIRTIDE; MARAVIROC; MEMANTINE; METHYLPHENIDATE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SELEGILINE; VALPROIC ACID; VIRUS VECTOR;

AGING; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; DRUG ABUSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENETIC SUSCEPTIBILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NEUROIMAGING; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SIMIAN VIRUS 40; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD; X RAY CRYSTALLOGRAPHY;

AIDS DEMENTIA COMPLEX; ANIMALS; BIOMEDICAL RESEARCH; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HUMANS; JOURNALISM, MEDICAL;

EID: 78650872625     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e328340fd42     Document Type: Review

References (211)

1. Singer EJ, Valdes-Sueiras M, Commins D, Levine AJ. Neurologic presentations of AIDS. Neurol Clin 2010; 28:253-275; doi: 10.1016/j.ncl.2009.09. 018.
2. Minagar A, Shapshak P. HIV associated dementia: clinical features and pathogenesis. In Minagar A, Shapshak P, editors. NEURO-AIDS. Hauppauge, New York: Nova Science Publ; 2006.
3. Fernandez F, Ruiz P, editors. Psychiatric aspects of HIV/ AIDS. Philadelphia, PA: Lippincott Williams and Wilkins; 2006.
4. Goodkin K. Virology, Immunology, Transmission, and disease stage. In Fernandez F, Ruiz P, editors. Psychiatric aspects of HIV/AIDS. Philadelphia, PA: Lippincott Williams and Wilkins; 2006. pp. 11-22.
5. Goodkin K, Verma A, Shapshak P, editors. The spectrum of NeuroAIDS disorders: pathophysiology, diagnosis, and treatment. Washington, DC: ASM Press; 2008.
6. Petito C, Kerza-Kwiatecki AP, Gendelman HE, McCarthy M, Nath A, Podack ER, et al. Neuronal injury in HIV infection. J Neurovirol 1999; 5:327-341.
7. Ironson G, Weiss SM, Lydston D, Tobin J, Lechner S, Ishii M, et al. The impact of improved self-efficacy on viral-load in culturally diverse women living with AIDS: the SMART/EST Women's Project. AIDS Care 2005; 17:222-236.
8. Resnick L, Berger JR, Shapshak P, Tourtellotte WW. Early penetration of the blood-brain-barrier by HTLV-III/LAV. Neurology 1988; 38:9-15.
9. Arendt G, Nolting T, Frisch C, Husstedt IW, Gregor N, Koutsi-lieri E, et al. Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease. J Neurovirol 2007; 13:225-232.
10. Tarasów E, Wiercińska-Drapało A, Kubas B, Dzienis W, Orzechowska-Bobkiewicz A, Prokopowicz D, et al. Cerebral MR spectroscopy in neurologically asymptomatic HIV-infected patients. Acta Radiol 2003; 44:206-212.
11. Minagar A, Commins D, Alexander JS, Hoque R, Chiappelli F, Singer EJ, et al. Diagnostics for NeuroAIDS: present and future. Molec Diagn Ther 2008; 12:25-43.
12. Power C, Boissé L, Rourke S, Gill MJ. NeuroAIDS: an evolving epidemic. Can J Neurol Sci 2009; 36:285-295.
13. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986; 19:517-524.
14. Klunder AD, Chiang MC, Dutton RA, Lee SE, Toga AW, Lopez OL, et al. Mapping cerebellar degeneration in HIV/AIDS. Neuroreport 2008; 19:1655-1659.
15. Cole MA, Castellon SA, Perkins AC, Ureno OS, Robinet MB, Reinhard MJ, et al. Relationship between psychiatric status and frontal-subcortical systems in HIV-infected individuals. J Int Neuropsychol Soc 2007; 13:549-554.
16. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, et al. Updated research nosology for HIV-associated neuro-cognitive disorders. Neurology 2007; 69:1789-1799; Epub 2007 Oct 3.
17. AAN (American Academy Neurology). Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991; 41:778-785.
18. Bhaskaran K, Mussini C, Antinori A, Walker AS, Dorrucci M, Sabin C, et al. Changes in the incidence and predictors of human immunodeficiency virus-associated dementia in the era of highly active antiretroviral therapy. Ann Neurol 2008; 63:213-221.
19. McArthur JC, McDermott MP, McClernon D, St. Hillaire, K, Conant K, Marder, et al. Attenuated central nervous system infection in advanced HIV/AIDS with combination antiretro-viral therapy. Arch Neurol 2004; 61:1687-1696.
20. Cysique LA, Maruff P, Brew BJ. Prevalence and pattern of neuropsychological impairment in human immunodeficiency virus-infected/acquired immunodeficiency syndrome (HIV/ AIDS) patients across pre and posthighly active antiretroviral therapy eras: a combined study of two cohorts. J Neurovirol 2004; 10:350-357.
21. Simioni S, Cavassini M, Annoni JM, Rimbault A, Abraham AR, Isabelle Bourquin, et al. Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010; 24:1243-1250.
22. Descamps M, Hyare H, Stebbing J, Winston A. Magnetic resonance imaging and spectroscopy of the brain in HIV disease. J HIV Ther 2008; 13:55-58.
23. Babiker AG, Peto T, Porter K, Walker AS, Darbyshire JH. Age as a determinant of survival in HIV infection. J Clin Epidemiol 2001; 54 (Suppl 1):S16-S21.
24. Valcour VC, Shikuma C, Shiramizu G, Watters M, Poff P, Selnes O, et al. Age, Apolipoprotein E4, and the risk of HIV dementia: the Hawaii Aging with HIV cohort. J Neuroimmu-nol 2004; 157:197-202. (Pubitemid 39576655)
25. Woods SP, Rippeth JD, Frol AB, Levy JK, Ryan E, Soukup VM, et al. Inter-rater reliability of clinical ratings and neurocog-nitive diagnoses in HIV. J Clin Exp Neuropsychol 2004; 26:759-778.
26. Everall I, Vaida F, Khanlou N, Lazzaretto D, Achim C, Letendre S, et al. Clinico-neuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol 2009; 15:360-370.
27. Petersen RC, Morris JC. Mild cognitive impairment as a clinical entity and treatment target. Arch Neurol 2005; 62:1160-1163.
28. Petersen RC, Parisi JE, Dickson DW, Johnson KA, Knopman DS, Boeve BF, et al. Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 2006; 63:665-672; doi: 10.1001/archneur.63.5.665. PMID 16682536.
29. Saito Y, Murayama S. Neuropathology of mild cognitive impairment. Neuropathology 2007; 6:58-84.
30. Whitwell JL, Shiung MM, Przybelski SA, Weigand SD, Knopman DS, Boeve BF, et al. MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment. Neurology 2008; 70:512-520; doi: 10.1212/ 01.wnl.0000280575.77437.a2. PMID 17898323.
31. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer's disease': revising the NINCDS-ADRDA criteria. Lancet Neurol 2007; 6:734-746.
32. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al. Consortiumon DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 2005; 65:1863-1872.
33. Roman GC, Tatemichi TK, Erkinjuntti T, Cummings JL, Masdeu JC, Garcia JH, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology 1993; 43:250-260.
34. Wiederkehr S, Simard M, Fortin C, van Reekum R. Validity of the clinical diagnostic criteria for vascular dementia: a critical review. Part II. J Neuropsychiatry Clin Neurosci 2008; 20:162-177.
35. Marra CM, Critchlow CW, Hook EW 3rd, Collier AC, Lukehart SA. Cerebrospinal fluid treponemal antibodies in untreated early syphilis. Arch Neurol 1995; 52:68-72.
36. Kaplan JE, Benson C, Holmes KH, Brooks JT, Pau A, Masur H. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 2009; 58:1-207; quiz CE1-4.
37. Portegies P, Solod L, Cinque P, Chaudhuri A, Begovac J, Everall I, et al. Guidelines for the diagnosis and management of neurological complications of HIV infection. Eur J Neurol 2004; 11:297-304.
38. Petito CK. Neuropathology of acquired immunodeficiency syndrome. In Nelson JS, Mena H, Parisi JS, Schochet SS, editors. The principles, practice of neuropathology. 2nd ed. New York: Oxford University Press; 2003. pp. 95-111.
39. Wang Y, Kirby JE, Qian Q. Effective use of JC virus PCR for diagnosis of progressive multifocal leukoencephalopathy. J Med Microbiol 2009; 58:253-255.
40. Cinque P, Bossolasco S, Bestetti A, Sala S, Pierotti C, Lazzarin A. Molecular studies of cerebrospinal fluid in human immunodeficiency virus type 1-associated opportunistic central nervous system diseases-: an update. J Neurovirol 2002; 8 (Suppl 2):122-128.
41. Cash WJ, McConville P, McDermott E, McCormick PA, Callender ME, McDougall NI. Current concepts in the assessment and treatment of hepatic encephalopathy. QJM 2010; 103:9-16.
42. Harper C, Butterworth R. Nutritional and metabolic disorders. In Graham DI, Lantos PL, editors. Greenfield's neuropathology. 7th ed. London: Arnold Publishing; 2002. pp. 607-651.
43. Dreibelbis JE, Jozefowicz RF. Neurologic complications of respiratory disease. Neurol Clin 2010; 28:37-43.
44. Auer RN, Sutherland GR. Hypoxia and related conditions. In Graham DI, Lantos PL, editors. Greenfield's neuropathology. 7th ed. London: Arnold Publishing; 2002. pp. 233-280.
45. Xu J, Ikezu T. The comorbidity of HIV-associated neurocog-nitive disorders and Alzheimer's disease: a foreseeable medical challenge in post-HAART era. J Neuroimmune Pharmacol 2009; 4:200-212.
46. Pulliam L. HIV regulation of amyloid beta production. J Neuroimmune Pharmacol 2009; 4:213-217.
47. Anthony IC, Ramage SN, Camie FW, Simmonds P, Bell JE. Accelerated Tau deposition in the brains of individuals infected with human immunodeficiency virus-1 before and after the advent of highly active antiretroviral therapy. Acta Neuropathol 2006; 111:529-538.
48. Khanlou N, Moore DJ, Chana G, Cherner M, Lazzaretto D, Dawes S, et al. Increased frequency of alpha-synuclein in the substantia nigra in human immunodeficiency virus infection. J Neurovirol 2009; 15:131-138.
49. Minagar A, Shapshak P, Duran EM, Kablinger AS, Alexander JS, Kelley RE, et al. HIV-associated dementia, Alzheimer's disease, multiple sclerosis, and schizophrenia: gene expression review. J Neurol Sci 2004; 224 (1-2):3-17.
50. Minagar A, Shapshak P, Fujimura R, Ownby R, Heyes M, Eisdorfer C. The role of macrophage/microglia and astrocytes in the pathogenesis of three neurologic disorders: HIV-associated dementia, Alzheimer disease, and multiple sclerosis. J Neurol Sci 2002; 202 (1-2):13-23.
51. Bell JE, Brettle RP, Chiswick A, Simmonds P. HIV encephalitis, proviral-load, and dementia in drug users and homosexuals with AIDS. Effect of neocortical involvement. Brain 1998; 121:2043-2052.
52. Kim MT, Hill MN. Validity of self-report of illicit drug use in young hypertensive urban African-American males. Addict Beh 2003; 28:795-802; doi: 10.1016/S0306-4603(01)00277-5. (Pubitemid 36513513)
53. Fiala M, Eshleman AJ, Cashman J, Lin J, Lossinsky AS, Suarez V, et al. Cocaine increases human immunodeficiency virus type 1 neuroinvasion through remodeling brain microvascular endothelial cells. J Neurovirol 2005; 11:281-291.
54. Peterson PK, Gekker G, Hu S, Lokensgard J, Portoghese PS, Chao CC. Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: implication of an atypical mu-opioid receptor. Neuropharmacology 1999; 38:273-278.
55. Rogers TJ, Peterson PK. Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol 2003; 24:116-121.
56. LiY,WangX, TianS,Guo CJ, Douglas SD,HoWZ. Methadone enhances human immunodeficiency virus infection of human immune cells. J Infect Dis 2002; 185:118-122.
57. Dhillon NK, Williams R, Peng F, Tsai YJ, Dhillon S, Nicolay B, et al. Cocaine-mediated enhancement of virus replication in macrophages: implications for human immunodeficiency virus-associated dementia. J Neurovirol 2007; 13:483-495.
58. Nair MP, Mahajan SD, Schwartz SA, Reynolds J, Whitney R, Bernstein Z, et al. Cocaine modulates dendritic cell-specific C type intercellular adhesion molecule-3-grabbing nonintegrin expression by dendritic cells in HIV-1 patients. J Immunol 2005; 174:6617-6626.
59. Reynolds JL, Mahajan SD, Bindukumar B, Sykes D, Schwartz SA, Nair MP. Proteomic analysis of the effects of cocaine on the enhancement of HIV-1 replication in normal human astrocytes (NHA). Brain Res 2006; 1123:226-236.
60. Liang H, Wang X, Chen H, Song L, Ye L, Wang SH, et al. Methamphetamine enhances HIV infection of macrophages. Am J Pathol 2008; 172:1617-1624.
61. Gaskill PJ, Calderon TM, Luers AJ, Eugenin EA, Javitch JA, Berman JW. Human immunodeficiency virus (HIV) infection of human macrophages is increased by dopamine: a bridge between HIV-associated neurologic disorders and drug abuse. Am J Pathol 2009; 175:1148-1159; doi: 10.2353/ajpath. 2009.081067.
62. Lee YW, Hennig B, Yao J, Toborek M. Methamphetamine induces AP-1 and NF-kappaB binding and transactivation in human brain endothelial cells. J Neurosci Res 2001; 66:583-591.
63. Mahajan SD, Aalinkeel R, Sykes DE, Reynolds JL, Bindukumar B, Fernandez SF, et al. Tight junction regulation by morphine and HIV-1 tat modulates blood-brain barrier permeability. J Clin Immunol 2008; 28:528-541.
64. Sharma HS, Ali SF. Alterations in blood-brain barrier function by morphine and methamphetamine. Ann N Y Acad Sci 2006; 1074:198-224.
65. Turchan J, Anderson C, Hauser KF, Sun Q, Zhang J, Liu Y, et al. Estrogen protects against the synergistic toxicity by HIV proteins, methamphetamine and cocaine. BMC Neurosci 2001; 2:3-11.
66. Bruce-Keller AJ, Turchan-Cholewo J, Smart EJ, Geurin T, Chauhan A, Reid R, et al. Morphine causes rapid increases in glial activation and neuronal injury in the striatum of inducible HIV-1 Tat transgenic mice. Glia 2008; 56:1414-1427.
67. Harrod SB, Mactutus CF, Fitting S, Hasselrot U, Booze RM. Intra-accumbal Tat1-72 alters acute and sensitized responses to cocaine. Pharmacol Biochem Behav 2008; 90:723-729.
68. Kuczenski R, Everall IP, Crews L, Adame A, Grant I, Masliah E. Escalating dose-multiple binge methamphetamine exposure results in degeneration of the neocortex and limbic system in the rat. Exp Neurol 2007; 207:42-51.
69. Chana G, Everall IP, Crews L, Langford D, Adame A, Grant I, et al. Cognitive deficits and degeneration of interneurons in HIVR methamphetamine users. Neurology 2006; 67:1486-1489.
70. Sacktor N, Tarwater PM, Skolasky RL, McArthur JC, Selnes OA, Becker J, et al. CSF antiretroviral drug penetrance and the treatment of HIV-associated psychomotor slowing. Neurology 2001; 57:542-555.
71. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, et al., and AIDS Clinical Trials Group 736 Study Team. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23:1359-1366.
72. Marra CM, LockhartD,Zunt JR, PerrinM, Coombs RW, Collier AC. Changes in CSF and plasma HIV-1 RNA and cognition after starting highly active antiretroviral therapy. Neurology 2003; 60:1388-1395.
73. Foudraine NA, Hoetelmans RM, Lange JM, de Wolf F, van Benthem BH, Maas JJ, et al. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine. Lancet 1998; 351:1547-1550.
74. Antinori A, Perno CF, Giancola ML, Forbici F, Ippolito G, Hoetelmans RM, et al. Efficacy of Cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41:1787-1793.
75. Letendre SL, van den Brande G, Hermes A, Woods SP, Durelle J, Beck JM, et al. Lopinavir with ritonavir reduces the HIV RNA level in cerebrospinal fluid. Clin Infect Dis 2007; 45:1511-1517.
76. Couzigou C, Seang S, Morand-Joubert L, Roque-Afonso AM, Escaut L, Vittecoq D. Efficacy of etravirine for treatment of acute HIV meningoencephalitis. Clin Infect Dis 2009; 48:e62-e65.
77. Schifitto G, Navia BA, Yiannoutsos CT, Marra CM, Chang L, Ernst T, et al. Memantine and HIV-associated cognitive impairment: a neuropsychological and proton magnetic resonance spectroscopy study. AIDS 2007; 21:1877-1886.
78. Schifitto G, Zhang J, Evans SR, Sacktor N, Simpson D, Millar LL, et al. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. Neurology 2007; 69:1314-1321. (Pubitemid 47482445)
79. Dewhurst S, Maggirwar SB, Schifitto G, Gendelman HE, Gelbard HA. Glycogen synthase kinase 3 beta (GSK-3 beta) as a therapeutic target in NeuroAIDS. J Neuroimmune Pharmacol 2007; 2:93-96.
80. Schifitto G, Peterson DR, Zhong J, Ni H, Cruttenden K, Gaugh M, et al. Valproic acid adjunctive therapy for HIV-associated cognitive impairment: a first report. Neurology 2006; 66:919- 921; Epub 2006 Mar 1.
81. Lee K, Vivithanaporn P, Siemieniuk RA, Krentz HB, Maingat F, Gill MJ, et al. Clinical outcomes and immune benefits of antiepileptic drug therapy in HIV/AIDS. BMC Neurol 2010; 10:44-48.
82. Sagot-Lerolle N, Lamine A, Chaix ML, Boufassa F, Aboulker JP, Costagliola D, et al. ANRS EP39 study. Prolonged valproic acid treatment does not reduce the size of latent HIV reservoir. AIDS 2008; 22:1125-1129.
83. Fujimura RK. Viral-load and HIV-l associated dementia: neu-ropathology and drug efficacy. In Minagar A, Shapshak P, editors. Chapter 5 in NeuroAIDS. 2005. pp. 101-119 [ISBN: 1-59454-610-X].
84. Fujimura RK, Goodkin K, Petito C, Douyon R, Feaster DJ, Concha M, et al. HIV-1 proviral DNA load across neuroana-tomic regions of individuals with evidence for HIV-1-asso-ciated dementia. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 16:146-152.
85. Fujimura RK, Khamis I, Shapshak P, Goodkin K. Regional quantitative comparison of multispliced to unspliced ratios of HIV-1 RNA copy number in infected human brain. J NeuroAIDS 2004; 2:45-60.
86. Zhao L, Galligan DC, Lamers SL, Yu S, Shagrun L, Salemi M, et al. High-level HIV-1 DNA concentrations in brain tissues differentiate patients with post-HAART AIDS dementia complex or cardiovascular disease from those with AIDS. Sci China C Life Sci 2009; 52:651-656.
87. Petito C, Hexin C, Angeline RM, Torres-Munoz J, Roberts B, Wood C. HIV infection of choroid plexus in AIDS and asymptomatic HIV-infected patients suggests that the choroid plexus may be a reservoir of productive infection. J NeuroVirol 1999; 5:670-677.
88. Zhou L, Ng T, Yuksel A, Wang B, Dwyer DE, Saksena NK. Short communication: absence of HIV infection in the choroid plexus of two patients who died rapidly with HIV-associated dementia. AIDS Res Hum Retroviruses 2008; 24:839-843.
89. Shiramizu B, Gartner S, Williams A, Shikuma C, Ratto-Kim S, Watters M, et al. Circulating proviral HIV DNA and HIV-associated dementia. AIDS 2005; 19:45-52; PubMed: 15627032.
90. Shiramizu B, Williams AE, Shikuma C, Valcour V. Amount of HIV DNA in peripheral blood mononuclear cells is proportional to the severity of HIV-1-associated neurocognitive disorders. J Neuropsychiatry Clin Neurosci 2009; 21:68-74; doi: 10.1176/appi.neuropsych.21.1.68.
91. Valcour VG, Shiramizu BT, Sithinamsuwan P, Nidhinandana S, Ratto-Kim S, Ananworanich J, et al. HIV DNA and cognition in Thai longitudinal HAART initiation cohort: SEARCH 001 cohort study. Neurol 2009; 72:992-998; doi: 10.1212/ 01.wnl.0000344404.12759.83.
92. Hightower GK, Letendre SL, Cherner M, Gibson SA, Ellis RJ, Wolfson TJ, et al. Select resistance-associated mutations in blood are associated with lower CSF viral-loads and better neuropsychological performance. Virology 2009; 394:243- 248; Sep 15 [Epub ahead of print].
93. Ancuta P, Kamat A, Kunstman KJ, Kim E-Y, Autissier P, Wurcel A, et al. Microbial translocation is associated with increased monocyte activation and dementia in AIDS patients. PLoS ONE 2008; 3:e2516; doi: 10.1371/journal.pone. 0002516.
94. Chiappelli F, Shapshak P, Commins D, Singer E, Minagar A, Oluwadara O, et al. Molecular epigenetics, chromatin, and NeuroAIDS/HIV. I. Immunopathological implications. Bioin-formation 2008; 3:47-52; PMID: 19052666.
95. Shapshak P, Chiappelli F, Commins D, Singer E, Levine AJ, Somboonwit C, et al. Molecular epigenetics, chromatin, and NeuroAIDS/HIV. II. Translational implications. Bioinforma-tion 2008; 3:53-57; PMID: 19052667.
96. Tatro ET, Scott ER, Nguyen TB, Salaria S, Banerjee S, Moore DJ, et al. Evidence for alteration of gene regulatory networks through microRNAs of the HIV-infected brain: novel analysis of retrospective cases. PLoS One 2010; 5:e10337 [doi:10.1371/journal.pone.0010337] (www.plosone.org).
97. Zárate S, Kosakovsky-Pond SL, Shapshak P, Frost SDW. A comparative study of methods for detecting sequence com-partmentalization in HIV-1. J Virol 2007; 61:6643-6651.
98. Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK. Independent evolution of human immunodeficiency virus (HIV) drug resistance mutations in diverse areas of the brain in HIV-infected patients, with and without dementia, on antiretroviral treatment. J Virol 2004; 78:10133-10148.
99. Burkala EJ, He J, West JT, Wood C, Petito C. Compartmenta-lization of HIV-1 in the central nervous system: role of the choroid plexus. AIDS 2005; 19:675-684.
100. Van Marle G, Henry S, Todoruk T, Sullivan A, Silva C, Rourke SB, et al. Human immunodeficiency virus type 1 Nef protein mediates neural cell death: a neurotoxic role for IP-10. Virology 2004; 329:302-318.
101. Chang J, Jozwiak R, Wang B, Ng T, Ge YC, Bolton W, et al. Unique HIV type 1 V3 region sequences derived from six different regions of brain: region-specific evolution within host-determined quasispecies. AIDS Res Hum Retr 1998; 14:25-30.
102. Shapshak P, Segal DM, Crandall K, Fujimura RK, Zhang BT, Xin KQ, et al. Independent evolution of HIV-1 in different brain regions. AIDS Res Hum Retr 1999; 15:811-820.
103. Caragounis EC, Gisslén M, Lindh M, Nordborg C, Westergren S, Hagberg L, et al. Comparison of HIV-1 pol and env sequences of blood, CSF, brain and spleen isolates collected ante-mortem and postmortem. Acta Neurol Scand 2008; 117:108-116.
104. Pillai SK, Pond SL, Liu Y, Good BM, Strain MC, Ellis RJ, et al. Genetic attributes of cerebrospinal fluid-derived HIV-1 env. Brain 2006; 129 (Pt 7):1872-1883; Epub 2006 May 30.
105. Salemi M, Lamers SL, Yu S, de Oliveira T, Fitch WM, McGrath MS. Phylodynamic analysisofhuman immunodeficiency virus type 1 in distinct brain compartments provides a model for the neuropathogenesis of AIDS. J Virol 2005; 79:11343-11352.
106. Liu P, Hudson LC, Tompkins MB, Vahlenkamp TW, Meeker RB. Compartmentalization and evolution of feline immunodeficiency virus between the central nervous system and periphery following intracerebroventricular or systemic inoculation. J Neurovirol 2006; 12:307-321.
107. Thompson KA, Churchill MJ, Gorry PR, Sterjovski J, Oelrichs RB, Wesselingh SL, et al. Astrocyte specific viral strains in HIV dementia. Ann Neurol 2004; 56:873-877.
108. Agopian K, Wei BL, Garcia JV, Gabuzda D. CD4 and MHC-I downregulation are conserved in primary HIV-1 Nef alleles from brain and lymphoid tissues, but Pak2 activation is highly variable. Virology 2007; 358:119-135.
109. Ohagen A, Devitt A, Kunstman KJ, Gorry PR, Rose PP, Korber B, et al. Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol 2003; 77:12336-12345.
110. Korber BT, Learn GH Jr, Mullins JI, Hahn BH, Wolinsky S. Protecting HIV databases. Nature 1995; 378:242-244.
111. Learn GH Jr, Korber BT, Foley B, Hahn BH, Wolinsky SM, Mullins JI. Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol 1996; 70:5720-5730.
112. Herbeck JT, Nickle DC, Learn GH Jr, Gottlieb GS, Curlin ME, Heath L, et al. Human immunodeficiency virus type 1 env evolves toward ancestral states upon transmission to a new host. J Virol 2006; 80:1637-1644.
113. Mefford ME, Gorry PR, Kunstman K, Wolinsky SM, Gabuzda D. Bioinformatic prediction programs underestimate the frequency of CXCR4 usage by R5X4 HIV type 1 in brain and other tissues. AIDS Res Hum Retroviruses 2008; 24:1215-1220.
114. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, et al. Resistance to HIV-1 infection in Caucasian individuals bearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 1996; 382:722-725.
115. Boven LA, van der Bruggen T, van Asbecka BS, Marxa JJM, Nottet HSLM. Potential role of CCR5 polymorphism in the developmentofAIDS dementia complex. FEMS Immunol Med Microbiol 1999; 26 (3-4):243-247.
116. Singh KK, Barroga CF, Hughes MD, Chen J, Raskino C, McKinney RE, Spector SA. Genetic influence of CCR5, CCR2, and SDF1 variants on human immunodeficiency virus 1 (HIV-1)-related disease progression and neurological impairment, in children with symptomatic HIV-1 infection. J Infect Dis 2003; 188:1461-1472.
117. Spector SA, Singh KK, Gupta S, Cysique LA, Jin H, Letendre S, et al., Heaton RK; HNRC Group. APOE epsilon4 and MBL-2 O/O genotypes are associated with neurocognitive impairment in HIV-infected plasma donors. AIDS 2010; 24:1471-1479.
118. Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, et al. Immunology NCfHAV. Common genetic variation and the control of HIV-1 in humans. PLoS Genet 2009; 5:e1000791.
119. Singh KK, Ellis RJ, Letendre S, Heaton R, Grant I, Spector SA. CCR2 polymorphisms affect neuropsychological impairment in HIV-1-infected adults. J Neuroimmunol 2004; 157 (1-2): 185-192.
120. Diaz-Arrastia R, Gong Y, Kelly CJ, Gelman BB. Host genetic polymorphisms in human immunodeficiency virus-related neurologic disease. J Neurovirol 2004; 10 (Suppl 1): 67-73.
121. Pemberton LA, Stone E, Price P, van Bockxmeer F, Brew BJ. The relationship between ApoE, TNFA, IL1a, IL1b and IL12b genes and HIV-1-associated dementia. HIV Med 2008; 9:677-680.
122. Corder EH, Robertson K, Lannfelt L, Bogdanovic N, Eggertsen G, Wilkins J, et al. HIV-infected subjects with the (4 allele for APOE have excess dementia and peripheral neuropathy. Nat Med 1998; 4:1182-1184.
123. Burt TD, Agan BK, Marconi VC, He W, Kulkarni H, Mold JE, et al. Apolipoprotein (Apo) (4 enhances HIV-1 cell entry in vitro, and the APOE (4/(4 genotype accelerates HIV disease progression. Proc Natl Acad Sci US 2008; 105:8718- 8723.
124. Dunlop O, Goplen AK, Liestøl K, Myrvang B, Rootwelt H, Christophersen B, et al. HIV dementia and apolipoprotein E. Acta Neurol Scand 1997; 95:315-318.
125. Levine AJ, Singer EJ, Sinsheimer JS, Hinkin CH, Papp J, Dan-dekar S, et al. CCL3 genotype and current depression increase risk of HIV-associated dementia. Neurobeh HIV Med 2009; 1:1-7.
126. Gonzalez E, Rovin BH, Sen L, Cooke G, Dhanda R, Mummidi S, et al. HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels. Proc Natl Acad Sci USA 2002; 99:13795-13800.
127. Singh KK, Hughes MD, Chen J, Spector SA. Impact of MCP-1-2518-G allele on the HIV-1 disease of children in the United States. AIDS 2006; 20:475-478.
128. Quasney MW, Zhang Q, Sargent S, Mynatt M, Glass J, McArthur J. Increased frequency of the tumor necrosis factor-alpha-308 A allele in adults with human immunodeficiency virus dementia. Ann Neurol 2001; 50:157-162.
129. Winkler C, Modi W, Smith MW, Nelson GW, Wu X, Carring-ton M, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998; 279:389-393.
130. Shrestha S, Strathdee SA, Galai N, Oleksyk T, Fallin MD, Mehta S, et al. Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis 2006; 193:16-26.
131. Price P, James I, Fernandez S, French MA. Alleles of the gene encoding IL-1alpha may predict control of plasma viraemia in HIV-1 patients on highly active antiretroviral therapy. AIDS 2004; 18:1495-1501.
132. Levine AJ, Singer EJ, Shapshak P. The role of host genetics in the susceptibility for HIV-associated neurocognitive disorders. AIDS Behav 2009; 13:118-132.
133. Pomara N, Belzer KD, Silva R, Cooper TB, Sidtis JJ. The apolipoprotein E (4 allele and memory performance in HIV-1 seropositive subjects: differences at baseline but not after acute oral lorazepam challenge. Psychopharmacology 2008; 201:125-135.
134. Ferris MJ, Mactutus CF, Booze RM. Neurotoxic profiles of HIV, psychostimulant drugs of abuse, and their concerted effect on the brain: current status of dopamine system vulnerability in NeuroAIDS. Neurosci Biobehav Rev 2008; 32:883-909.
135. Bousman CA, Cherner M, Atkinson JH, Grant I, Tsuang MT, Everall IP. Impact of the catechol-O-methyl-transferase Val158Met polymorphism on executive functioning in the contextofHIV-infection and methamphetamine dependence. Neurobehav HIV Med 2010; 2:1-11; PMCID: PMC2804107.
136. Borjabad A, Brooks AI, Volsky DJ. Gene expression profiles of HIV-1-infected glia and brain: toward better understanding of the role of astrocytes in HIV-1-associated neurocognitive disorders. J Neuroimmune Pharmacol 2009 [Epub ahead of print] PubMed PMID: 19697136.
137. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature 2001; 410:988-994.
138. Shapshak P, Duncan D, Minagar D, Rodriguez de la Vega P, Stewart R, Petito CK. Elevated expression of IFN-g in the HIV-1 infected brain. Front Biosci 2004; 9:1073-1081.
139. Nicolini A, Ajmone-Cat MA, Bernardo A, Levi G, Minghetti L. Human immunodeficiency virus type-1 Tat protein induces nuclear factor (NF)-kappaB activation and oxidative stress in microglial cultures by independent mechanisms. J Neuro-chem 2001; 79:713-716.
140. Hurwitz AA, Lyman WD, Berman JW. Tumor necrosis factor alpha and transforming growth factor beta upregulated astro-cyte expression of monocyte chemo-attractant protein-1. J Neuroimmunol 1995; 57:193-198.
141. Erichsen D, Lopez AL, PengH, Niemann D, Williams C, Bauer M, et al. Neuronal injury regulates fractalkine: relevance for HIV-1 associated dementia. J Neuroimmunol 2003; 138:144-155.
142. Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, et al. CXCR-4 activated astrocyte glutamate release via TNF-alpha: amplification by microglia triggers neurotoxi-city. Nat Neurosci 2001; 4:702-710.
143. Fine SM, Angel RA, Perry SW, Epstein LG, Rothstein JD, Dewhurst S, et al. Tumor necrosis factor alpha inhibits glu-tamate uptake by primary human astrocytes. Implications for pathogenesis of HIV-1 dementia. J Biol Chem 1996; 271: 15303-15306.
144. Yeh MW, Kaul M, Zheng J, Nottet HS, Thylin M, Gendelman HE, et al. Cytokine-stimulated, but not HIV-infected, human monocyte-derived macrophages produce neurotoxic levels of L-cysteine. J Immunol 2000; 164:4265-4270.
145. Haughey NJ, Cutler RG, Tamara A, McArthur JC, Vargas DL, Pardo CA, et al. Perturbation of sphingolipid metabolism and ceramide production in HIV-dementia. Ann Neurol 2004; 55:257-267.
146. Nath A, Conant K, Chen P, Scott C, Major EO. Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem 1999; 274:17098-17102.
147. Viviani B, Corsini E, Binaglia M, Galli CL, Marinovich M. Reactive oxygen species generated by glia are responsible for neuron death induced by human immunodeficiency virus-glycoprotein 120 in vitro. Neuroscience 2001; 107:51-58.
148. Samikkannu T, Saiyed ZM, Rao KV, Babu DK, Rodriguez JW, Papuashvili MN, et al. Differential regulation of indoleamine-2,3-dioxygenase (IDO) by HIV type 1 clade B and C Tat protein. AIDS Res Hum Retroviruses 2009; 25:329-335.
149. Geschwind DH. DNA microarrays: translation of the genome from laboratory to clinic. Lancet Neurol 2003; 2:275-282.
150. Shapshak P, Minagar A, Duran EM, Ziegler F, Davis W, Seth R, et al. Gene expression in HIV associated dementia. In: Min-agar A, Alexander JS, editors. Inflammatory disorders of the nervous system, clinical aspects, pathogenesis, and management. Totowa, NJ: Humana Press; 2005.
151. Albright AV, González-Scarano F. Microarray analysis of activated mixed glial (microglia) and monocyte-derived macrophage gene expression. J Neuroimmunol 2004; 157:27-38; PubMed PMID: 15579277.
152. Galey D, Becker K, Haughey N, Kalehua A, Taub D, Woodward J, et al. Differential transcriptional regulation by human immunodeficiency virus type 1 and gp120 in human astro-cytes. J Neurovirol 2003; 9:358-371; PubMed PMID: 12775419.
153. Roberts ES, Zandonatti MA, Watry DD, Madden LJ, Henriksen SJ, Taffe MA, et al. Induction of pathogenic sets of genes in macrophages and neurons in NeuroAIDS. Am J Pathol 2003; 162:2041-2057; PubMed PMID: 12759259; PubMed Central PMCID: PMC1868118.
154. Masliah E, Robert ES, Langford D, Everall I, Crews L, Adame A, et al. Patterns of gene dysregulation in the frontal cortex of patients with HIV encephalitis. J Neuroimmun 2004; 157:163-175.
155. Hanson LR, Frey WH. Strategies for intranasal delivery of therapeutics for the prevention and treatment of NeuroAIDS. J Neuroimmune Pharmacol 2007; 2:81-86.
156. Agrawal L, Louboutin JP, Reyes BA, Van Bockstaele EJ, Strayer DS. Antioxidant enzyme gene delivery to protect from HIV-1 gp120-induced neuronal apoptosis. Gene Ther 2006; 13:1645-1656.
157. Zink MC. Translational research models and novel adjunctive therapies for NeuroAIDS. J Neuroimmune Pharmacol 2007; 2:14-19.
158. Louboutin JP, Agrawal L, Reyes BA, Van Bockstaele EJ, Strayer DS. Protecting neurons from HIV-1 gp120-induced oxidant stress using both localized intracerebral and generalized intraventricular administration of antioxidant enzymes delivered by SV40-derived vectors. Gene Ther 2007; 14:1650-1661.
159. Infanti JL. Challenging the gold standard: should mannitol remain our first-line defense against intracranial hypertension? J Neurosci Nurs 2008; 40:362-368.
160. Sigurdsson EM, Wadghiri YZ, Mosconi L, Blind JA, Knudsen E, Asuni A, et al. T. A nontoxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging 2008; 29:836-847.
161. Xu J, Ma C, Bass C, Terwilliger EF. A combination of mutations enhances the neurotropism of AAV-2. Virology 2005; 341:203-214.
162. Terzi D, Zachariou V. Adeno-associated virus-mediated gene delivery approaches for the treatment of CNS disorders. Biotechnol J 2008; 3:1555-1563.
163. Romano G. Current development of adeno-associated viral vectors. Drug News Perspect 2005; 18:311-316.
164. Lu Y. GFP-lentiviral vectors targeting for NeuroAIDS. Methods Mol Biol 2009; 515:177-197.
165. Letendre S, Marquie-Beck J, Capparelli E, Best B, Clifford D, Collier AC, et al. CHARTER Group. Validation of the CNS Penetration-Effectiveness rank for quantifying antiretroviral penetration into the central nervous system. Arch Neurol 2008; 65:65-70.
166. Letendre S, Ellis R, Ances B, McCutchan. Neurologic complications if HIV disease and their treatment. Topics HIV Med 2010; 18:45-55.
167. DeLuca A, Ciancio B, Larussa D, Murri R, Cingolani A, Rizzo MG, et al. Correlates of independent HIV-1 replication in the CNS and of its control by antiretrovirals. Neurology 2002; 59:342-347.
168. Gollapudi S, Gupta S. Human immunodeficiency virus I-induced expression of P-glycoprotein. Biochem Biophys Res Commun 1990; 171:1002-1007.
169. Yao SY, NgAM, Sundaram M, Cass CE, Baldwin SA, Young JD. Transport of antiviral 3'-deoxy-nucleoside drugs by recombi-nant human and rat equilibrative, nitro-benzyl-thio-inosine (NBMPR)-insensitive (ENT2) nucleoside transporter proteins producedin Xenopus oocytes. Mol Membr Biol 2001; 18:161-167.
170. Minuesa G, Purcet S, Erkizia I, Molina-Arcas M, Bofill M, Izquierdo-Useros N, et al. Expression and functionality of antihuman immunodeficiency virus and anticancer drug uptake transporters in immune cells. J Pharmacol Exp Ther 2008; 324:558-567; Epub 2007 Nov 27.
171. Sturmer E, von Moltke LL, Perloff MD, Greenblatt DJ. Differential modulation of P-glycoprotein expression and activity by nonnucleoside HIV-1 reverse transcriptase inhibitors in cell culture. Pharm Res 2002; 19:1038-1045.
172. Gibbs JE, Jayabalan P, Thomas SA. Mechanisms by which 2',3'-dideoxyinosine (ddI) crosses the guinea-pig CNS barriers; relevance to HIV therapy. J Neurochem 2003; 84:725-734.
173. Baldwin SA, Beal PR, Yao SY, King AE, Cass CE, Young JD. The equilibrative nucleoside transporter family, SLC29. Pflugers Arch 2004; 447:735-743; Epub 2003 Jun 28.
174. Jung N, Lehmann C, Rubbert A, Knispel M, Hartmann P, van Lunzen J, et al. Relevance of the organic cation transporters 1 and 2 for antiretroviral drug therapy in human immunodeficiency virus infection. Drug Metab Dispos 2008; 36: 1616-1623; Epub 2008 May 19.
175. Kim AE, Dintaman JM, Waddell DS, Silverman JA. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998; 286:1439-1445.
176. Lee LS, Soon GH, Shen P, Yong EL, Flexner C, Pham P. Darunavir/ritonavir and Efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers. Antivir Ther 2010; 15:275-279.
177. Fujimoto H, Higuchi M, Watanabe H, Koh Y, Ghosh AK, Mitsuya H, et al. P-glycoprotein mediates efflux transport of darunavir in human intestinal Caco-2 and ABCB1 gene-transfected renal LLC-PK1 cell lines. Biol Pharm Bull 2009; 32:1588-1593.
178. Vierling P, Greiner J. Prodrugs of HIV protease inhibitors. Curr Pharm Des 2003; 9:1755-1770.
179. Eilers M, Roy U, Mondal D. MRP (ABCC) transporters-mediated efflux of anti-HIV drugs, Saquinavir and zidovu-dine, from human endothelial cells. Exp Biol Med (Maywood) 2008; 233:1149-1160; Epub 2008 Jun 5.
180. Zastre JA, Chan GN, Ronaldson PT, Ramaswamy M, Couraud PO, Romero IA, et al. Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line. J Neurosci Res 2009; 87:1023-1036.
181. Gupta A, Zhang Y, Unadkat JD, Mao Q. HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther 2004; 310:334-341; Epub 2004 Mar 8.
182. Perloff MD, von Moltke LL, Fahey JM, Greenblatt DJ. Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells. J Pharm Pharmacol 2007; 59:947-953.
183. Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 2010; 87:735-742; Epub 2010 Feb 10.
184. Walker DK, Bowers SJ, Mitchell RJ, Potchoiba MJ, Schroeder CM, Small HF. Preclinical assessment of the distribution of Maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 2008; 38:1330-1339.
185. Price RW, Parham R, Kroll JL, Wring SA, Baker B, Sailstad J, et al. Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther 2008; 13:369-374.
186. Morris KA, Davies NWS, Brew BJ. A guide to interpretation of neuroimmunological biomarkers in the combined antiretro-viral therapy-era of HIV central nervous system disease. Neurobehav HIV Med 2010; 2:59-72; doi: 10.2147/ NBHIV.S7167.
187. Diesing TS, Swindells S, Gelbard H, Gendelman HE. HIV-1-associated dementia: a basic science and clinical perspective. AIDS Read 2002; 12:358-368.
188. Smits HA, Boven LA, Pereira CF, Verhoef J, Nottet HS. Role of macrophage activation in the pathogenesis of Alzheimer's disease and human immunodeficiency virus type 1-associated dementia. Eur J Clin Invest 2000; 30:526-535.
189. Ghafouri M, Amini S, Khalili K, Sawaya BE. HIV-1 associated dementia: symptoms and causes. Retrovirology 2006; 3:28-35.
190. Alter G, Ananworanich J, Pantophlet R, Rybicki EP, Buonaguro L. Report on the AIDS vaccine 2008 conference. Hum Vaccine 2009; 5:119-125.
191. Bass E, Feuer C, Warren M. AIDS vaccine research and advocacy: an update. BETA 2009; 21:24-30.
192. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361:2209-2220.
193. Koff WC, Berkley SF. The renaissance in HIV vaccine development-: future directions. N Engl J Med 2010.
194. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, Finzi A, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010.
195. Zolla-Pazner S, Cardozo T. Structure-function relationships of HIV-1 envelope sequence-variable regions refocus vaccine design. Nature Rev Immunol 2010; 10:527-535; doi: 10.1038/ nri2801.
196. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, Seaman MS, et al. Rational design of envelope surface identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 2010; 329:856-861; doi: 10.1126/science.1187659.
197. Kangueane P, Kayathri R, Kishore M, Flower DR, Sadler K, Chiappelli F, et al. Designing HIV gp120 peptide vaccines: rhetoric or reality for NeuroAIDS, Chapter 9. In Goodkin K, Shapshak P, Verma A, editors. The spectrum of NeuroAIDS disorders: pathophysiology, diagnosis, and treatment. Washington, DC: ASM Press; 2008. pp. 105-119.
198. De Groot AS, MarconL,Bishop EA, RiveraD,KutzlerM,Weiner DB, et al. HIV vaccine development by computer-assisted design: the GAIA vaccine. Vaccine 2005; 23:2136-2148.
199. Mohanapriya A, Nandagond S, Shapshak P, Kangueane U, Kangueane P. A HLA-DRB supertype chart with potential overlapping peptide binding function. Bioinformation 2010; 4:300-309.
200. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L. Central nervous system damage produced by expression of the HIV-1 coat protein gp120 in transgenic mice. Nature 1994; 367:188-193.
201. Michaud J, Fajardo R, Charron G, Sauvageau A, Berrada F, Ramla D, et al. Neuropathology of NFHgp160 transgenic mice expressing HIV-1 env protein in neurons. J Neuropathol Exp Neurol 2001; 60:574-587.
202. Kim BO, Liu Y, Ruan Y, Xu ZC, Schantz L, He JJ. Neuropathol- ogiesintransgenic mice expressing human immunodeficiency virus type 1 Tat protein under the regulation of the astrocyte-specific glial fibrillary acidic protein promoter and doxycy-cline. Am J Pathol 2003; 162:1693-1707.
203. Tyor WR, Power C, Gendelman HE, Markham RB. A model of human immunodeficiency virus encephalitis in SCID mice. PNAS, USA 1993; 90:8658-8662.
204. Hartman K. Feline immunodeficiency virus infection: an overview. Vet J 1998; 155:123-137.
205. Fox HS, Phillips TR. FIV and NeuroAIDS. J Neurovirol 2002; 8:155-157.
206. Manigat F, Vivithanaporn P, Zhu Y, Taylor A, Baker G, Pearson K, et al. Neurobehavioral performance in feline immunodeficiency virus infection: integrated analysis of viral burden, neuroinflammation, and neuronal injury in cortex. J Neurosci 2009; 29:8429-8437.
207. Ward JM, O'Leary TJ, Baskin GB, Benveniste R, Harris CA, Nara PL, et al. Immunohistochemical localization of human and simian immunodeficiency viral antigens in fixed tissue sections. Am J Pathol 1987; 127:199-205.
208. Watry D, Lane TE, Streb M, Fox HS. Transfer of neuropatho-genic simian immunodeficiency virus with naturally infected microglia. Am J Pathol 1995; 146:914-923.
209. Zink MC, Suryanarayana K, Mankowski JL, Shen A, Piatak M Jr, Spelman JP, et al. High viral-load in the cerebrospinal fluid and brain correlates with severity of simian immunodeficiency virus encephalitis. J Virol 1999; 73:10480-10488.
210. Novembre FJ, DeRosayro J, O'Neil SP, Anderson DC, Klumpp SA, McClure HM. Isolation and characterization of a neuro-pathogenic simian immunodeficiency virus derived from a sooty mangabey. J Virol 1998; 72:8841-8851.
211. Williams K, Westmoreland S, Greco J, Ratai E, Lentz M, Kim WK, et al. Magnetic resonance spectroscopy reveals that activated monocytes contribute to neuronal injury in SIV NeuroAIDS. J Clin Invest 2005; 115:2534-2545.